Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N
SLN.OQ - Silence Therapeutics PLC
Silence Therapeutics PLC to Discuss Topline Results from Phase 2 SANRECO Study of Divesiran
Aug 10, 2026 / 12:00PM GMT
=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thanks, everyone, for joining us. With me today are Ian Ross, our Chairman and Interim Principal Executive Officer, who will provide some opening comments, and Steve Romano, our Chief R&D Officer, who will review the Sanrico study and top-line results. We will then open the call to your questions. Rhonda Helms, our Chief Financial Officer, is also joining us on the line and available for questions. Today's press release and presentation are available on our corporate website at silence-therapeutics.com/events.
Before we begin, I would like to remind you that this call will contain remarks concerning Silence's future expectations, clinical development plans, and prospects
Trustpilot
